Full-Time

Bioinformatics Scientist

Tempus

Tempus

1,001-5,000 employees

AI-driven precision medicine through clinical and molecular data analysis

Data & Analytics
AI & Machine Learning

Mid

Remote + 3 more

Required Skills
Python
R
Data Structures & Algorithms
Requirements
  • Experience in cancer genetics, immunology, or molecular biology
  • Experience working with next-generation sequencing data
  • Self-driven and works well in interdisciplinary teams
  • Experience with communicating insights and presenting concepts to a diverse audience
  • Demonstrated programming ability
  • Background in predictive or prognostic algorithm development
  • Strong background in the development of statistical models
Responsibilities
  • Design and conduct analysis to improve variant calling, classification and analysis systems
  • Translate insight from model systems into predictors and classifiers of therapeutic response and prognosis in clinical cancer care
  • Collaborate with scientists, and clinicians to design and perform analyses on cancer clinical sequencing data in order to improve quality of care
  • Work in interdisciplinary groups of scientists, engineers, and product developers to translate research into clinically actionable insights for our clients
  • Develop algorithms used to gain insight into cancer variation through analysis of next generation sequencing data
  • Produce high quality and detailed documentation for all projects
Desired Qualifications
  • Must have completed a Ph.D. in Cancer Biology or Molecular Biology related to cancer
  • Computational skills using R, Bioconductor, and/or Python

Tempus Labs, Inc. is a leader in precision medicine, leveraging artificial intelligence to analyze vast clinical and molecular data, enabling physicians to deliver personalized, data-driven care. The company's advanced machine learning platform and unique solution sets facilitate the discovery, development, and delivery of optimized therapeutic options for patients. With a focus on extensive molecular profiling, Tempus has developed a robust pan-cancer tumor organoid platform and validated a liquid biopsy assay, demonstrating their commitment to transforming personalized patient care and their position at the forefront of the healthcare industry.

Company Stage

Series G

Total Funding

$1.3B

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

5%

1 year growth

32%

2 year growth

52%
INACTIVE